Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000466784 | SCV000554943 | likely benign | Neurofibromatosis, type 1 | 2024-04-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002318540 | SCV000670511 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2024-10-06 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000611864 | SCV000718695 | likely benign | not specified | 2017-04-24 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Genome- |
RCV000466784 | SCV002561221 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000611864 | SCV005202395 | likely benign | not specified | 2024-07-28 | criteria provided, single submitter | clinical testing |